Department of Gastroenterology, L. Sacco University Hospital, Milano, Italy.
Eur J Gastroenterol Hepatol. 2009 Apr;21(4):387-93. doi: 10.1097/MEG.0b013e3283069db0.
To investigate the course of dyspeptic symptoms, predictors of symptom relief and use of antidyspeptic drugs in patients with duodenal ulcer disease and functional dyspepsia 6-7 years after successful Helicobacter pylori eradication.
Patients with H. pylori-positive duodenal ulcer or functional dyspepsia, included in a prospective, randomized study from January 1996 to June 1997, and successfully treated with standard triple therapy, were eligible. After 6-7 years, case histories of 142 patients were retrieved and patients were interviewed by telephone. They were asked about the presence of dyspeptic symptoms and health care needs during the last week and over the last 6-7 years. Predictive factors of complete long-term relief of symptoms have been evaluated.
Of the 114 eligible patients, 104 (49 with duodenal ulcer and 55 with functional dyspepsia) were included in the study. The mean duration of follow up was 6.6+/-0.5 years. Complete relief of dyspeptic symptoms was reported, in this period, by 49.0% of duodenal ulcer patients and 36.4% of patients with functional dyspepsia (P=0.271). Persistence of symptoms within 3 months of H. pylori eradication and female sex were predictive of persistence of symptoms in the following 6-7 years, in patients with functional dyspepsia. In turn, approximately 50% of the patients with complete symptom remission, within 6 months of H. pylori eradication, later became symptomatic. Since the end of the H. pylori eradication trial, 26.9% of patients were still using or had used antidyspeptic drugs; patients with functional dyspepsia having used them more frequently than duodenal ulcer patients (36.4 vs. 16.3%; P=0.037).
In clinical practice, long-term symptomatic benefit, in duodenal ulcer patients, after H. pylori eradication, is similar to that in patients with functional dyspepsia. Early evaluation of symptoms after successful H. pylori eradication may be predictive of outcome in dyspeptic patients. Most symptomatic patients did not seek antidyspeptic drugs. Use of antisecretory medications was, however, greater in patients with functional dyspepsia than in duodenal ulcer patients.
研究十二指肠溃疡和功能性消化不良患者在成功根除幽门螺杆菌 6-7 年后,消化不良症状的进程、症状缓解的预测因素以及抗消化不良药物的使用情况。
这项前瞻性、随机研究纳入了 1996 年 1 月至 1997 年 6 月期间符合条件的幽门螺杆菌阳性十二指肠溃疡或功能性消化不良患者,并采用标准三联疗法进行治疗。6-7 年后,检索了 142 例患者的病历,并通过电话对患者进行了访谈。询问他们在过去一周和过去 6-7 年中是否存在消化不良症状和医疗需求。评估了完全长期缓解症状的预测因素。
在 114 例符合条件的患者中,有 104 例(49 例十二指肠溃疡和 55 例功能性消化不良)纳入了这项研究。平均随访时间为 6.6+/-0.5 年。在此期间,49.0%的十二指肠溃疡患者和 36.4%的功能性消化不良患者报告完全缓解消化不良症状(P=0.271)。在根除幽门螺杆菌后 3 个月内症状持续存在和女性是功能性消化不良患者在随后 6-7 年内症状持续存在的预测因素。相反,在根除幽门螺杆菌后 6 个月内症状完全缓解的患者中,约有 50%的患者后来出现症状。自根除幽门螺杆菌试验结束以来,26.9%的患者仍在使用或曾使用过抗消化不良药物;功能性消化不良患者比十二指肠溃疡患者更频繁地使用这些药物(36.4%比 16.3%;P=0.037)。
在临床实践中,十二指肠溃疡患者根除幽门螺杆菌后长期的症状获益与功能性消化不良患者相似。成功根除幽门螺杆菌后早期评估症状可能对消化不良患者的预后有预测作用。大多数有症状的患者没有寻求抗消化不良药物。然而,功能性消化不良患者使用抗分泌药物的情况比十二指肠溃疡患者更多。